S. Hallmeyer

发表

Abstract CT114: The MITCI (Phase 1b) study: A novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients with or without previous immune checkpoint therapy treatment

G. Daniels, B. Curti, M. Faries, 2017 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Noninvasive Assessment of the Circle of Willis in Cerebral Ischemia: The Potential of CT Angiography and Contrast-Enhanced Transcranial Color-Coded Duplexsonography

H. Reichmann, R. von Kummer, G. Gahn, 1999, Cerebrovascular Diseases.

Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E

G. Linette, A. Ribas, H. Tawbi, 2017, Melanoma research.

Management of Breast Cancer during Pregnancy: Are We Compliant with Current Guidelines?

S. Hallmeyer, B. Parilla, Victoria Shlensky, 2017, American Journal of Perinatology Reports.

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

M. Suarez‐Almazor, J. Wolchok, M. Atkins, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Integrative Tumor Board: Recurrent Lymphoma

D. Peace, S. Hallmeyer, 2004 .

Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146–154 peptide

J. Sosman, N. Mahmud, D. Peace, 2006, Cancer Immunology, Immunotherapy.

An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma

S. Patel, G. Daniels, W. Sharfman, 2021, Oncoimmunology.

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma

R. Sullivan, J. Kirkwood, S. Patel, 2016, Journal of Immunotherapy for Cancer.

CALM study: A phase II study of an intratumorally delivered oncolytic immunotherapeutic agent, coxsackievirus A21, in patients with stage IIIc and stage IV malignant melanoma.

J. Nemunaitis, G. Daniels, H. Kaufman, 2014 .

CALM study: A phase II study of intratumoral coxsackievirus A21 in patients with stage IIIc and stage IV malignant melanoma.

J. Nemunaitis, G. Daniels, H. Kaufman, 2013 .

Contrast-enhanced transcranial color-coded duplexsonography in stroke patients with limited bone windows.

H. Reichmann, R. Ackerman, R. von Kummer, 2000, AJNR. American journal of neuroradiology.

Cerebrovascular reserve before and after vertebral artery angioplasty.

H. Bourquain, R. von Kummer, G. Gahn, 1999, AJNR. American journal of neuroradiology.

Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline.

M. Diefenbach, P. Ganz, B. Andersen, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Deterministic--chaotic and periodic properties of heart rate and arterial pressure fluctuations and their mediation in piglets.

U Zwiener, B Walter, M Eiselt, 1996, Cardiovascular research.

Sequencing of New and Old Therapies for Metastatic Melanoma

J. Richards, S. Hallmeyer, M. Ratterman, 2016, Current Treatment Options in Oncology.

Real‐world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study

A. Abernethy, M. Highley, S. Dalle, 2016, Cancer medicine.

Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma

Meihua Wang, G. Daniels, H. Kaufman, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM

N. Agarwal, M. Fishman, S. Patel, 2016, Clinical genitourinary cancer.

Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial.

V. Sondak, T. Karrison, D. Olson, 2020 .

Phase II trial of pembrolizumab (pembro) plus 1 mg/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel).

V. Sondak, T. Karrison, D. Olson, 2018 .

A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States

G. Linette, J. Hainsworth, K. Flaherty, 2014, Cancer journal.

Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma

M. Ross, K. Harrington, J. Nemunaitis, 2016, Head & neck.

High-Dose Radiation as a Dramatic, Immunological Primer in Locally Advanced Melanoma

J. Richards, S. Hallmeyer, M. Mohiuddin, 2015, Cureus.

Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma

V. Sondak, T. Karrison, D. Olson, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract CT214: Phase II CALM study: Changes in the tumor microenvironment induced by the immunotherapeutic agent coxsackievirus A21 delivered intratumorally in patients with advanced melanoma

B. Curti, R. Andtbacka, D. Shafren, 2015 .

Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma.

J. Nemunaitis, G. Daniels, H. Kaufman, 2015 .

Phase II calm extension study: Coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment

B. Fox, C. Bifulco, B. Curti, 2015, Journal of Immunotherapy for Cancer.

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update

M. Somerfield, I. Makhoul, A. Eisen, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Prospective, Longitudinal Evaluation of SARS-CoV-2 COVID-19 Exposure, Use of Protective Equipment and Social Distancing in a Group of Community Physicians

A. Rivelli, E. Ehrenpreis, S. Hallmeyer, 2022, Healthcare.

Docetaxel and Oxaliplatin as First-Line Therapy for Advanced Non-Small Cell Lung Cancer: A Phase II Trial

C. Nabhan, S. Hallmeyer, D. Milton, 2009, Journal of chemotherapy.

Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic Malignancies.

M. Thompson, S. Hallmeyer, J. Weese, 2022, Journal of patient-centered research and reviews.

Characteristics of patients with hematologic malignancies without seroconversion post-COVID-19 third vaccine dosing

M. Thompson, S. Hallmeyer, J. Weese, 2022, medRxiv.

A History of Cancer Survivorship Plans

S. Hallmeyer, N. Cheema, 2015 .

1130TiPNEMO: A PHASE 3 TRIAL OF BINIMETINIB (MEK162) VERSUS DACARBAZINE IN PATIENTS WITH ADVANCED NRAS-MUTANT MELANOMA WHO ARE UNTREATED OR HAVE PROGRESSED AFTER ANY NUMBER OF IMMUNOTHERAPY REGIMENS.

D. Schadendorf, K. Flaherty, P. Ascierto, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

1103PCALM STUDY: SECONDARY ENDPOINTS OF A PHASE II STUDY OF A NOVEL ONCOLYTIC IMMUNOTHERAPEUTIC AGENT, COXSACKIEVIRUS A21, DELIVERED INTRATUMORALLY IN PATIENTS WITH ADVANCED MALIGNANT MELANOMA.

J. Nemunaitis, G. Daniels, H. Kaufman, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.